Zealand Pharma enters agreement to use DCAI’s Gefion AI supercomputer to accelerate drug discovery
DCAI today announces that Zealand Pharma, a biotechnology company transforming the future of metabolic health, will use Gefion to strengthen and accelerate drug discovery.
Working with DCAI, Zealand Pharma will be able to integrate enterprise-scale artificial intelligence into its drug discovery and development workflows, generating proprietary insights that further enhance the quality and efficiency of medicine creation as the Company executes its Metabolic Frontier 2030 strategy.
Gefion’s advanced supercomputing power—featuring over 1,500 NVIDIA GPUs running entirely on renewable energy—will allow Zealand Pharma to leverage its 25 years of expertise in peptide research to conduct large-scale protein and peptide simulations, providing a level of computational performance not previously possible. The platform supports advanced characterization, simulation, and generative AI modeling for drug discovery and design.
"By integrating DCAI’s powerful AI infrastructure into our research workflows, Zealand Pharma is fundamentally transforming our approach to peptide discovery and design,” said Utpal Singh, Chief Scientific Officer of Zealand Pharma.
"Gefion’s computational power will generate new insights that augment the expertise of our scientists. These enhanced capabilities directly support our Metabolic Frontier 2030 strategy, including our ambition to deliver more than 10 clinical programs and achieve industry-leading cycle times from idea to clinic by 2030. Combined with our deep peptide expertise, this computationally driven approach positions Zealand Pharma to lead the next generation of metabolic health innovation while maintaining the rigorous scientific standards that define our leadership in peptide therapeutics.”
Nadia Carlsten, CEO of DCAI, said "Working with Zealand Pharma marks a significant important milestone for DCAI as we continue to accelerate life sciences and biotechnology through impactful AI. It’s rewarding to see innovative customers use our AI capabilities and translate them into measurable scientific and clinical outcomes: by providing scalable AI computing for Zealand Pharma’s peptide discovery initiatives, we can help reduce development timelines and contribute to innovative metabolic treatments for patients around the world.”
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.